Mistral Pharma Inc.

Mistral Pharma Inc.

December 03, 2007 07:59 ET

Mistral Pharma Announces Positive Results From a Pilot PK Study on MIST-B04

Study validates new TRIZERO™ delivery platform

MONTREAL, QUEBEC--(Marketwire - Dec. 3, 2007) - Mistral Pharma Inc. (TSX VENTURE:MIP) ("Mistral") today announced positive results from a first pilot pharmacokinetic (PK) study on a new controlled-release product, MIST-B04. The results of this pilot study clearly show that MIST-B04 presents a pharmacokinetic profile leading to a once daily dosing schedule compared to the three times daily immediate-release formulation presently on the market. MIST-B04 is formulated using a new drug delivery platform named TRIZERO™, which was developed internally by Mistral's scientists and for which a patent application was filed in June 2007.

"We are very excited by these positive results on MIST-B04" commented Bertrand Bolduc. "They show that our brand new TRIZERO™ platform is performing very well in vivo and this opens up many other opportunities for line-extension products for MIST-B04" he added.

Mistral's MIST-B04 is a controlled-delivery branded product in the rheumatology / inflammation field. According to Drug Topics, sales for the branded product targeted by MIST-B04 were more than US$ 200 M in the US in 2006.

About Mistral Pharma Inc.

Mistral Pharma Inc. is an innovative pharmaceutical company that is active in the reformulation and the commercialization of already-marketed drugs. Its branded drug delivery products, MIST-B01, MIST-B02, MIST-B03 & MIST-B04, showed positive results at their respective first pilot clinical trials. Mistral also markets INSTILLAGEL® in Canada, a local anesthetic and antiseptic combination product used for urology procedures. Mistral has also in-licensed TAMALIS™ (Rupatadine) a new antihistamine and INSTILLAQUILL®, a single use extension tube used in gynecology. They should both be filed with Health Canada in 2008. Mistral positions itself as a development and marketing partner for pharmaceutical companies. More information is available on Mistral's website at www.mistralpharma.com.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on Management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, results from clinical studies and regulatory approval process as well as general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President & Chief Executive Officer
    514-421-1717 # 2224
    Mistral Pharma Inc.
    Alain Provencher, CA, CF
    Vice-president, Finance & Chief Financial Officer
    514-421-1717 # 2222